Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Teduglutide
Drug ID BADD_D02137
Description Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012.
Indications and Usage Treatment of short bowel syndrome (SBS), malabsorption associated with the removal of the intestine, in adults patients who are dependent on parenteral support.
Marketing Status Not Available
ATC Code A16AX08
DrugBank ID DB08900
KEGG ID D06053
MeSH ID C494910
PubChem ID 16139605
TTD Drug ID D00RCI
NDC Product Code 17337-0264; 68875-0102; 41524-0009; 63557-1031; 68875-0101; 68875-0103; 68225-087; 68594-001
Synonyms teduglutide | Gly(2)-GLP-2 | (Gly2)GLP-2
Chemical Information
Molecular Formula C164H252N44O55S
CAS Registry Number 197922-42-2
SMILES CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C (CCC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC(=O )N)NC(=O)C(C(C)CC)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O) C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(= O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CC(=O)N)NC(=O)C(CCSC)NC(=O)C(CCC(=O)O)NC(=O)C(C C(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C NC(=O)C(CC5=CN=CN5)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
SarcomaInsulin-like growth factor IP05019T6093026266067
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Cardiac failure congestive02.05.01.002--Not Available
Cholecystitis09.03.01.001--
Cholecystitis acute09.03.01.003--Not Available
Cholelithiasis09.03.01.002--Not Available
Cholestasis09.01.01.001--Not Available
Cough22.02.03.001--
Duodenal polyp16.05.03.002; 07.20.01.008--Not Available
Flatulence07.01.04.002--
Fluid overload14.05.06.001; 02.05.04.004--Not Available
Gallbladder perforation12.01.02.005; 09.03.02.002--
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Hypothyroidism14.11.01.012; 05.02.03.001--
Injection site reaction12.07.03.015; 08.02.03.014--
Intestinal obstruction07.13.01.002--Not Available
Intestinal stenosis07.13.01.003--Not Available
Nausea07.01.07.001--
Pancreatic pseudocyst07.18.03.002--Not Available
Pancreatitis acute07.18.01.002--Not Available
Pancreatitis chronic07.18.01.007--Not Available
Sleep disorder19.02.04.001--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Vomiting07.01.07.003--
Mental status changes19.07.01.001--Not Available
Intestinal polyp16.05.01.002; 07.20.01.009--Not Available
Gallbladder polyp16.06.02.002; 09.03.02.003--Not Available
Colorectal adenocarcinoma07.21.01.007; 16.13.01.009--Not Available
Lung neoplasm malignant22.08.01.001; 16.19.02.001--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages